Oramed Pharmaceuticals is no longer a clinical-stage oral insulin developer. The March close with Lifeward converted the Protein Oral Delivery platform into a large minority stake in a small medical-robotics issuer and left Oramed as a healthcare holding company with no product revenue of its own. Reported profit in the latest quarter is a mark on a single oncology stake, not cash earned from operations. The investment debate is whether the discount to book is a cheap look-through on Alpha Tau or a correct haircut for concentration, collection risk, and thin cash.
First-half net income of about $116 million arrived against an operating loss of roughly $6 million and zero revenue. Almost all of that income is a revaluation of Alpha Tau shares and warrants that together sit near $211 million on the mid-year balance sheet. Cash fell to about $15 million after a special dividend, new investments, and tax withholdings on equity awards. The profit line therefore tracks one listed oncology name rather than any franchise the company still operates.
The next tests sit outside the income statement. Scilex still owes a mid-year installment that had not arrived by the August filing date, with a late-September cash-or-shares deadline. Alpha Tau's ReSTART skin-cancer readout is due around year-end or early next year. The open question is whether the holding-company discount closes if those two events land cleanly, or whether the market keeps treating Oramed as an illiquid wrapper around one clinical-stage oncology name.